# Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)

> **NCT00165035** · PHASE3 · COMPLETED · sponsor: **Cordis US Corp.** · enrollment: 1701 (actual)

## Conditions studied

- Coronary Disease

## Interventions

- **DEVICE:** CoStar Paclitaxel Drug Eluting Coronary Stent System
- **DEVICE:** TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent

## Key facts

- **NCT ID:** NCT00165035
- **Lead sponsor:** Cordis US Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2007-01
- **Final completion:** 2011-07
- **Target enrollment:** 1701 (ACTUAL)
- **Last updated:** 2011-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165035, "Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00165035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*